Compare LGCB & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGCB | ELUT |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 23.3M |
| IPO Year | 2023 | 2020 |
| Metric | LGCB | ELUT |
|---|---|---|
| Price | $1.78 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 78.6K | ★ 585.7K |
| Earning Date | 07-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,993,265.00 | ★ $21,746,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.80 | ★ 24.08 |
| 52 Week Low | $1.22 | $0.50 |
| 52 Week High | $6.83 | $3.52 |
| Indicator | LGCB | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 59.70 |
| Support Level | $1.75 | $0.60 |
| Resistance Level | $2.17 | $0.73 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 29.17 | 79.83 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The Company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.